Evandro D. Bezerra, MD

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses real-world findings of brexucabtagene autoleucel in relapsed/refractory B-cell ALL.

In an interview with Targeted Oncology, Evandro D. Bezerra, MD, discusses brexucabtagene autoleucel for relapsed/refractory B-cell ALL.

Evandro D. Bezerra, MD, provides real-world data from the CIBMTR Registry, examining the effectiveness of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.